head and neck cancer – Page 5

Mandibular reconstruction using plates prebent to fit rapid prototyping 3-dimensional printing models ameliorates contour deformity

Source: 7thspace.comAuthors: Masaki Azuma, Toru Yanagawa, Naomi Ishibash Kanno, Fumihiko Uchida, Takaaki Ito, Kenji Yamagata, Shogo Hasegawa, Kaoru Sasaki, Koji Adachi, Katsuhiko Tabuchi, Mitsuru Sekido and Hiroki Bukawa Recently, medical rapid prototyping (MRP) models, fabricated with computer-aided design and computer-aided manufacture (CAD/CAM) techniques, have been applied to reconstructive surgery in the treatment of head and neck cancers. Here, we tested the use of preoperatively manufactured reconstruction plates, which were produced using MRP models. The clinical efficacy and esthetic outcome of using these products in mandibular reconstruction was evaluated. Methods: A series of 28 patients with malignant oral tumors underwent unilateral segmental resection of the mandible and simultaneous mandibular reconstruction. Twelve patients were treated with prebent reconstruction plates that were molded to MRP mandibular models designed with CAD/CAM techniques and fabricated on a combined powder bed and inkjet head three-dimensional printer. The remaining 16 patients were treated using conventional reconstruction methods. The surgical and esthetic outcomes of the two groups were compared by imaging analysis using post-operative panoramic tomography. Results: The mandibular symmetry in patients receiving the MRP-model-based prebent plates was significantly better than that in patients receiving conventional reconstructive surgery. Conclusions: Patients with head and neck cancer undergoing reconstructive surgery using a prebent reconstruction plate fabricated according to an MRP mandibular model showed improved mandibular contour compared to patients undergoing conventional mandibular reconstruction. Thus, use of this new technology for mandibular reconstruction results in an improved esthetic outcome with the potential for improved quality of life for patients. *This news story [...]

Charlotte Parker2014-10-23T16:48:30-07:00October, 2014|Oral Cancer News|

Proteomic analysis of oral/head and neck cancer

Source: http://cancerres.aacrjournals.orgAuthor: Shen Hu, Lifeng Zhang, Jiang Jiang, Martha Arellano-Garcia, and David Wong Abstract: The stagnant survival rates over the past few decades for patients with oral/head and neck squamous cell carcinoma (OSCC/HNSCC) emphasize the need for identifying novel diagnostic and therapeutic targets based on molecular profiling of the tumor. In this study, we have conducted patient-based proteomic analysis towards the discovery of potential serum and tissue protein targets associated with OSCC/HNSCC. First, we have utilized quantitative proteomics based on gel electrophoresis and stable isotope labeling/tandem mass spectrometry (MS/MS) to identify differentially expressed serum proteins between lymph-node metastatic and non-metastatic OSCCs. Proteins in PAGE gel bands were digested and the resulting peptides were labeled with iTRAQ reagents and subsequently quantified with liquid chromatography (LC) with quadrupole time-of-flight MS or linear ion trap MS (LTQ). The differentially expressed proteins included transthyretin, alpha-fibrinogen, tetranectin, hemopexin, ficolin, HGF activator, plasminogen, clusterin, etc. Second, we have performed comparative proteomic analysis of human papillomavirus (HPV)-positive and HPV-negative HNSCCs because HPV has been recognized as an important risk factor for a subset of OSCC/HNSCC. Differentially expressed proteins were revealed by 2-D gel electrophoresis and then identified using in-gel tryptic digestion followed by LC-MS/MS (linear ion trap). Interesting targets associated with HPV-positive HNSCC included NHEJ1, PARK7 (oncogene DJ-1), superoxide dismutase, heat shock protein beta-1, fatty acid-binding protein, etc. NHEJ1 is a DNA repair protein involved in DNA nonhomologous end joining whereas PARK7 acts as a positive regulator of androgen receptor-dependent transcription and has cell-growth promoting and transforming activities. In addition, [...]

Charlotte Parker2014-10-10T11:26:28-07:00October, 2014|Oral Cancer News|

Early detection of head and neck cancer: development of a novel screening tool using multiplexed immunobead-based biomarker profiling

Source: http://cancerres.aacrjournals.org Authors: Faina Linkov, Alex Lisovich, Zoya Yurkovetsky, Adele Marrangoni, Lyudmila Velikokhatnaya, Brian Nolen, Matthew Winans, William Bigbee, Jill Siegfried, Anna Lokshin, and Robert Ferris Abstract: Squamous cell carcinoma of the head and neck cancer (SCCHN) is an aggressive disease which has been linked to altered immune, inflammatory, and angiogenesis responses. A better understanding of these aberrant responses might improve early detection and prognosis of SCCHN and provide novel therapeutic targets. Previous studies examined the role of multiplexed serum biomarkers in small cohorts or SCCHN sera. We hypothesized that an expanded panel comprised of multiple cytokines, chemokines, growth factors, and other tumor markers, which individually may show some promising correlation with disease status, might provide higher diagnostic power if used in combination. Thus, we evaluated a novel multi-analyte LabMAP profiling technology that allows simultaneous measurement of multiple serum biomarkers. Concentrations of 60 cytokines, growth factors, and tumor antigens were measured in the sera of 116 SCCHN patients prior to treatment (active disease group), 103 patients who were successfully treated (no evidence of disease, NED, group), and 117 smoker controls without evidence of cancer. The multi-marker panel offering the highest diagnostic power was comprised of 25 biomarkers, including EGF, EGFR, IL-8, tPAI-1, AFP, MMP-2, MMP-3, IFN-α, IFN-γ, IP-10, RANTES, MIP-1α, IL-7, IL-17, IL-1Rα, IL-2R, G-CSF, mesothelin, IGFBP-1, E-selectin, cytokeratin (CK)19, V-CAM, and CA-125. Statistical analysis using an ADE algorithm resulted in a sensitivity of 84.5%, specificity of 98%, and 92% of patients in the active disease group correctly classified from a [...]

Charlotte Parker2014-10-10T11:05:56-07:00October, 2014|Oral Cancer News|

Alcohol drinking in never-tobacco users and cigarette smoking in never drinkers: pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium

Source: http://cancerres.aacrjournals.orgAuthors: Paolo Boffetta, Mia Hasibe & On Behalf Of INHANCE Consortium Abstract: Cigarette smoking and alcohol drinking account for at least 75% of head and neck cancers. A precise understanding of the independent effect of each of these factors in the absence of the other has important implications, in terms of elucidating the mechanisms of head and neck carcinogenesis and assessing the effect of interventions aimed to control either risk factor.We determined the extent to which head and neck cancer is associated with cigarette smoking among never-drinkers and alcohol drinking among never-tobacco users. We pooled individual-level data across 15 individual case-control studies including 10,244 head and neck cancer cases and 15,227 controls.There were 1,072 cases and 5,775 controls who never used tobacco, and 1,598 cases and 4,051 controls who never drank alcohol. Cigarette smoking increased the risk of head and neck cancers [odds ratio (OR)=2.10, 95% confidence interval (CI) 1.49-2.95] among never-drinkers, with clear dose-response relationships for frequency, duration and packyears of cigarette smoking. Approximately 24% of head and neck cancer cases among non-drinkers would have been prevented if these individuals had not smoked cigarettes. Among never-tobacco users, an increasing risk of head and neck cancer was detected for increasing alcohol drinking frequency (p for trend<0.001), but the effect was apparent only at high doses.Our results represent the most precise estimate available of the independent effect of each of the two main risk factors of head and neck cancer and exemplify the strengths of large-scale consortia in cancer epidemiology. *This news [...]

Charlotte Parker2014-10-10T10:36:00-07:00October, 2014|Oral Cancer News|

AACR says that new drug may assist therapy for Head and Neck Cancer

Source: hcplive.comAuthor: THURSDAY, Sept. 18, 2014 (HealthDay News) -- The investigational drug alpelisib (previously known as BYL719) appears to inhibit activation of the pathway that leads to resistance to cetuximab, an anti-epidermal growth factor receptor agent used in the treatment of head and neck cancer. These findings were presented at the American Association for Cancer Research's special conference "Targeting the PI3K-mTOR Network in Cancer," held from Sept. 14 to 17 in Philadelphia. Pamela Munster, MD, of the University of California in San Francisco, and colleagues tested the combination of BYL719 and cetuximab in vivo in a cetuximab-sensitive and a cetuximab-resistant xenograft model of esophageal squamous cell carcinoma. In a phase Ib study, BYL719 was administered in combination with cetuximab in adults with recurrent or metastatic squamous cell carcinoma of the head and neck that was resistant or intolerant to platinum-based chemotherapy; prior cetuximab therapy was allowed. The researchers found that the addition of BYL719 to cetuximab showed an additive effect in the cetuximab-sensitive model. BYL719 restored sensitivity to cetuximab in the cetuximab-resistant model. In the phase Ib study, as of March 10, 2014, 37 patients have received BYL719 and cetuximab, and the overall response rate is 11%. Based on the data from preclinical studies and the phase Ib study, the combination of alpelisib and cetuximab for squamous cell carcinoma of the head and neck is being explored in a phase II study. "Treatment resistance is often conveyed through activation of the PI3K/AKT/mTOR pathway, and alpelisib is an inhibitor of this pathway," [...]

Charlotte Parker2014-09-22T12:45:41-07:00September, 2014|Oral Cancer News|

The Cancer Cure Parents Aren’t Using

Source: washingtonpost.comAuthor: Meredith Wadman Not so long ago, when my sons still had smooth cheeks and children’s voices, I had them vaccinated against human papillomavirus, the most common sexually transmitted disease. It was late 2011, and the Centers for Disease Control and Prevention had just recommended that boys join girls in being vaccinated at age 11 or 12. I was certainly receptive: HPV, as it’s commonly called, causes cervical cancer, cancer of the tonsils, cancer of the back of the tongue and, less often, cancers of the vulva, vagina, anus and penis. It seemed important to ensure that my kids were protected. Yet numbers released last month by the CDC show that my sons, now 14 and 15, are among a small minority of adolescent males who have been vaccinated. In 2013, just 14 percent of American boys ages 13 to 17 had received all three recommended doses of the HPV vaccine. (The CDC also recommends “catch-up” vaccination for males up to age 21.) Not that parents are rushing to have their girls vaccinated either, even though the CDC first recommended the vaccine for prepubescent girls in 2007 and virtually all insurers pay for it. In 2013, fewer than 38 percent of American girls between 13 and 17 had received the full three-dose course. It is heartbreaking to watch a safe, effective vaccine go unused. Consider this: The CDC estimates that increasing the vaccination rate of American girls to 80 percent would prevent 53,000 cervical cancers during the lifetimes of girls who are now 12 and younger. When [...]

Charlotte Parker2014-08-25T11:08:26-07:00August, 2014|Oral Cancer News|

Curt Schilling Reveals his Diagnosis of Oral Cancer and Believes Chewing Tobacco was the Cause

Source: boston.comAuthor: Steve Silva Curt Schilling, the former Red Sox pitcher and ESPN analyst, announced today during the WEEI/NESN Jimmy Fund Radio Telethon that he was diagnosed with squamous cell carcinoma -- which is cancer in the mouth -- in February. "This all came about from a dog bite," Schilling said. "I got bitten by a dog and I had some damage to my finger and I went to see a doctor, and the day that I went to see the doctor, I was driving and I went to rub my neck and I felt a lump on the left side of my neck. And I knew immediately it wasn't normal. So there happened to be an ENT [Ear, Nose, and Throat] right next door to the hand doctor, and I thought what the heck, let me just stop in and see and so I waited in the office and went in there and they did the biopsy, and two days later, they diagnosed me with squamous cell carcinoma. "You know what the amazing thing was? And I was just dumbfounded by it. You've just been told you have cancer and you walk out into the public and the world's still going on and it was really a challenge to wrap my head around that. My second thought was, 'Yeah, really, you think I can handle this too?' So after a couple of tests, I got sent over to Brigham and Women's and Dana-Farber and that's where I met Dr. Haddad [...]

Charlotte Parker2014-08-20T11:31:16-07:00August, 2014|Oral Cancer News|

New Study Finds Editing HPV Genes Kills Cancer

Source: drbicuspid.comAuthor: DrBicuspid Staff August 14, 2014 -- Researchers have hijacked a defense system normally used by bacteria to fend off viral infections and redirected it against human papillomavirus (HPV), the virus that causes cervical, head and neck, and other cancers, according to a new study in the Journal of Virology (August, 6, 2014). Using a genome editing tool, researchers from Duke University were able to selectively destroy two viral genes responsible for the growth and survival of cervical carcinoma cells, causing the cancer cells to self-destruct. The study findings validate an approach only recently attempted in mammalian cells, and they could help in the development of antiviral strategies against other DNA-based viruses such as hepatitis B and herpes simplex. "Because this approach is only going after viral genes, there should be no off-target effects on normal cells," said senior study author Bryan R. Cullen, PhD, a professor of molecular genetics and microbiology at the Duke University School of Medicine, in a statement. "You can think of this as targeting a missile that will destroy a certain target. You put in a code that tells the missile exactly what to hit, and it will only hit that, and it won't hit anything else because it doesn't have the code for another target." When examining the genomes of different types of bacteria, researchers noted long stretches where the same genetic sequence was repeated. But in between these repeated stretches were DNA sequences that varied from bacteria to bacteria. About a decade ago, researchers determined that [...]

Charlotte Parker2014-08-14T17:25:10-07:00August, 2014|Oral Cancer News|

Tumour Suppressor Mutations Alone Cannot Explain Deadly Cancer

Source: www.domain-b.comAuthor: Staff Although mutations in a gene dubbed ''the guardian of the genome'' are widely recognized as being associated with more aggressive forms of cancer, researchers at the University of California, San Diego School of Medicine, have found evidence suggesting that the deleterious health effects of the mutated gene may in large part be due to other genetic abnormalities, at least in squamous cell head and neck cancers. The study, published online 3 August in the journal Nature Genetics, shows that high mortality rates among head and neck cancer patients tend to occur only when mutations in the tumour suppressor gene coincide with missing segments of genetic material on the cancer genome's third chromosome. The link between the two had not been observed before because the mutations co-occur in about 70 per cent of head and neck tumours and because full genetic fingerprints of large numbers of cancer tumours have become available only recently. ''These two genetic malfunctions are not two separate stab wounds to the body,'' says co-senior author Trey Ideker, PhD, chief of the division of genetics. ''One exposes the Achilles tendon and the other is a direct blow to it.'' To patients with these cancers, the study's results mean that there may be therapeutic value in testing tumours for the two genetic identifiers, known as a TP53 mutation (short for tumour protein 53) and a 3p deletion (short for deletions of genetic information on the short arm ''p'' of the third chromosome). TP53 plays a key role in [...]

Charlotte Parker2014-08-08T10:12:06-07:00August, 2014|Oral Cancer News|

Study finds low public awareness of head and neck cancer

Source: www.sciencecodex.comAuthor: The JAMA Network Journals Bottom Line: Public awareness of head and neck cancer (HNC) is low, with few Americans knowing much about risk factors such as tobacco use and human papillomavirus (HPV). Author: Alexander L. Luryi, B.S., of the Yale University School of Medicine, New Haven, Conn. Background: HNC is the 10 th most common cancer in the United States. It is a potentially preventable disease with about 75 percent of cases caused by tobacco use. In recent years, HPV has been established as a risk factor for HNC. Increased public awareness of HNC and its risk factors could help improve outcomes. How the Study Was Conducted: An online study of 2,126 adults was conducted in 2013. Results: About 66 percent of the participants were "not very" or "not at all" knowledgeable about HNC. Smoking and chewing or spitting tobacco were identified by 54.5 percent and 32.7 percent of respondents as risk factors for mouth and throat cancer, respectively. Only 0.8 percent of respondents identified HPV as a risk factor. Discussion: "Awareness of HNC is low compared with other cancers, which is concerning given the importance of risk factor avoidance and modification, as well as early patient detection, as drivers of prevention and improved outcomes." *This news story was resourced by the Oral Cancer Foundation, and vetted for appropriateness and accuracy.

Charlotte Parker2014-06-06T10:19:47-07:00June, 2014|Oral Cancer News|